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also resulted in a positive short- and long-term health
economic benefit in acutely ill medical patients. The
health-economic benefit of enoxaparin was positively re-
lated with the length of the follow-up period and a higher
risk for recurrence of VTE and mortality in asymptom-
atic patients.
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The post-thrombotic syndrome (PTS) is a serious long-
term complication of deep-vein thrombosis (DVT) that
may only be avoided by preventing the initial DVT. No
pharmacoeconomic assessment of low molecular weight
heparin (LMWH) has included the impact of reducing
these long-term complications in the UK.
OBJECTIVES: To determine the cost effectiveness of
LMWH (enoxaparin, 7 days, 40 mg daily) versus unfrac-
tionated heparin (UFH, 7 days, 15,000 units daily) for
the universal prophylaxis of DVT and PTS in patients un-
dergoing total hip replacement surgery (THRS).
METHODS: A probabilistic health-state transition model
using a Monte-Carlo (MC) simulation was developed to
project the long-term cost-effectiveness of the two strate-
gies in a cohort of 10,000 patients. The risk of develop-
ing a DVT in the short term (i.e., two weeks) was esti-
mated using epidemiological and clinical trial data. Patients
who survived a DVT in the short term were exposed to
the long-term risk of PTS and recurrent VTE whereas
other surviving patients were only exposed to the long-
term risk of idiopathic PTS and VTE. Economic literature
and expert opinion served as input for the model’s re-
source use and costs for DVT prophylaxis, clinical diag-
nosis and treatment of DVT, PE, and PTS. Five thousand
MC simulations were run on the model.
RESULTS: In the baseline, point-estimate analysis, LMWH
use prevented 240 DVTs and 13 deaths in the short term
compared to UFH, and resulted in net savings of £10 per
patient. In the long term, LMWH saved an additional
£36 in DVT complication costs. LMWH was the domi-
nant strategy in 70% of cases and was cost-effective in
72% overall.
CONCLUSION: This is the first economic analysis com-
paring LMWH and UFH that includes the long-term
complications of DVT. Our model indicates that the in-
clusion of these long-term complications supports the
widespread use of LMWH in patients undergoing THRS.
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OBJECTIVE: To estimate the cost-effectiveness of carvedilol
relative to bisoprolol as adjunctive beta blocker (BB) ther-
apy in patients with chronic heart failure.
METHODS: Comparison of survival benefits was per-
formed using the CIBIS-II placebo group as a representa-
tive cohort not treated with a BB. Using parametric sur-
vival analysis, five-year survival estimates were calculated
for bisoprolol and carvedilol based on published data for
the major mortality studies of the two BBs with similar
placebo mortality risks (CIBIS-II (hazard ratio 0.66) and
US Carvedilol Trial Program (hazard ratio 0.35)). Lim-
ited and extended benefit scenarios were estimated under
varying assumptions about the sustainability of BB treat-
ment effect. Under the limited benefits scenario the treat-
ment effect was conservatively assumed to last only until
the end of the reported trial periods. The extended bene-
fits scenario was assumed to persist up to five years. Tak-
ing the perspective of the UK NHS we estimated differ-
ences in treatment costs (medication, outpatient/GP visits,
hospitalization), and absolute mortality benefits to form
an incremental cost-effectiveness ratio.
RESULTS: The estimated benefit per patient at five years
under the extended benefits scenario was 145 days (0.398
yr.) for bisoprolol and 301 days (0.823 yr.) for carvedilol.
The corresponding figures for the limited benefits scenario
are 93 days (0.254 yr.) for bisoprolol and 119 days (0.325
yr.) for carvedilol. Over five years the estimated incremen-
tal cost-effectiveness ratio of carvedilol compared to biso-
prolol is £5,900 per LYG under limited and £1,800 per
LYG under extended benefit scenarios respectively.
CONCLUSIONS: Carvedilol represents a cost-effective
adjunctive treatment compared to bisoprolol in patients
with chronic heart failure. Statistical extrapolation indi-
cates that the relatively greater mortality benefits associ-
ated with carvedilol relative to bisoprolol are accrued at a
cost, which compares favourably with that of many other
common cardiovascular treatments such as statins and
ACE inhibitors.
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OBJECTIVE: The goal of this study is to evaluate and
determine the cost-effectiveness (CE) of a college of phar-
macy’s tobacco outreach program targeting thirteen- to
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fifteen-year-old adolescents, utilizing pharmacy students
as instructors.
METHODS: A cost-effectiveness study is conducted to
determine the cost per student who passed the knowledge
based exam on tobacco use, after attending the lecture
sessions of the tobacco outreach program. The primary
outcome of interest is the number of adolescents able to
pass the post-test, compared to the number able to pass
the pre-test. The following direct costs were collected:
supplies; materials; travel; consultant fees; primary inves-
tigator salary; coordinator salary; student teacher salary
and training; cost of classroom/space, and value of do-
nated goods. Only the incremental costs and outcomes
are utilized to calculate the CE ratio. No indirect costs or
discounting is included in the analysis.
RESULTS: A total of 132 students participated in the
program during a period of one year. The average cost
per student is $389.00. Pre-test and post-test are adminis-
tered to seventy-eight of these students. The cost-effec-
tiveness ratio per student who received a higher grade on
the post-test versus the pre-test is $689.59. The cost-effec-
tiveness ratio per student who received a grade greater
than seventy on the post-test compared to the pre-test is
$2,167.28.
CONCLUSIONS: This study evaluates the impact on the
post-test scores compared to the pre-test scores only. It
does not evaluate the impact of this program either on
behavioral changes associated with tobacco use, or on
the indirect benefit of being exposed to positive role mod-
els, the students from the college of pharmacy. The aver-
age per-student program cost of this study population is
consistent with published literature. However, very little
literature exists to determine if the CE ratios are within
the standards of other drug abuse educational programs.
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OBJECTIVE: To perform a retrospective economic anal-
ysis of The Coronary Angioplasty Amlodipine Restenosis
Study (CAPARES), in order to evaluate the pharmaco-
economic profile associated with the use of amlodipine in
patients undergoing angioplasty from the perspective of
the UK National Health Service
METHODS: A decision analysis was undertaken to track
the experiences of patients admitted for angioplasty who
were prescribed amlodipine versus those administered
placebo. The analysis modeled a four-month time period,
which included an initial hospitalization for angioplasty,
outpatient follow-up care and any re-admissions for car-
diovascular events. The CAPARES trial provided the out-
come data for the amlodipine and placebo patients. Out-
comes tracked in the analysis included MI, repeat PTCA,
CABG, and all-cause mortality. Economic data for inpa-
tient stays, procedures, physician services, laboratory
tests and pharmaceuticals were obtained from published
data, and a physician panel was used to estimate the
quantity of outpatient resource consumption.
RESULTS: The total expected cost per patient using and
not using amlodipine was £3,833 and £4,035, respec-
tively, resulting in a net cost savings of £202 over the
four-month time period. The cost savings is primarily due
to savings in inpatient costs due to the reduction in ad-
verse events requiring repeat revascularization and other
events requiring inpatient stays.
CONCLUSION: This analysis concludes that in addition
to the favourable clinical outcome for angioplasty pa-
tients using amlodipine versus placebo demonstrated in
the CAPARES trial, a net savings in overall costs may
also be realized, resulting in dominance.
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OBJECTIVES: MEDENOX, a multinational double-
blind, placebo-controlled trial (n  1102) of venous
thromboembolism (VTE) prophylaxis among hospital-
ized, acutely ill. Medical patients revealed a lower inci-
dence of VTE among patients receiving enoxaparin 40
mg once daily for 6-14 days relative to placebo (5.5%
versus 14.9% p  .001). Conducted in Europe and Can-
ada, the trial did not include a prospective economic
component. The purpose of this study was to model the
cost-effectiveness of VTE prophylaxis with enoxaparin in
a US health-care environment from the payer perspective.
METHODS: From a national sample of US hospital sum-
mary bills, we extracted records (n  374,855) of dis-
charges matching MEDENOX diagnostic/demographic
characteristics (primary diagnoses: acute infectious dis-
ease, acute respiratory failure, or heart failure, mean age:
73 years). With these data we estimated a multivariate
model of admission cost. Regression parameters were in-
corporated in a pharmacoeconomic model of hospital ad-
mission for patients treated with or without enoxaparin
per the MEDENOX protocol. Using Monte Carlo simu-
lation, the model projected cost of admission as a func-
tion of diagnosis, length of stay, VTE prophylaxis/no
prophylaxis. Outcome measures included cost of admis-
sion, cost for VTE prophylaxis, and incremental prophy-
laxis cost per VTE avoided. Not included were potential
downstream costs for inpatient or post-hospital VTE
treatment.
RESULTS: In the base case analysis, VTE prophylaxis ac-
